{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT06905197","nct_id":"NCT06905197","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06905197. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Experimental: Part A Dose Escalation monotherapy cohorts (20 mg once daily [QD])","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: Part A Dose Escalation monotherapy cohorts (40 mg QD)","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: Part A Dose Escalation monotherapy cohorts (60 mg QD)","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: Part A Dose Escalation monotherapy cohorts (90 mg QD)","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: Part A Dose Escalation monotherapy cohorts (120 mg QD)","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: Part A Dose Escalation monotherapy cohorts (150 mg QD)","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: Experimental: Part A Dose Escalation Combination cohorts (Combination dose 1)","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: Experimental: Part A Dose Escalation Combination cohorts (Combination dose 2)","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: Part A Dose Escalation Combination cohorts (Combination dose 3)","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: Part B Dose Expansion cohort A1 (selected dose 1)","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: Experimental: Part B Dose Expansion cohort A2 (selected dose 2)","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: Experimental: Part B Dose Expansion cohort B1 (selected dose 1)","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: Experimental: Part B Dose Expansion cohort B2 (selected dose 2)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer"],"enrollment":{"count":140,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"DZD6008","type":"DRUG"},{"name":"Sunvozertinib","type":"DRUG"}],"last_update":"2026-02-27","lead_sponsor":"Dizal Pharmaceuticals","official_title":"A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN1)","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part A: To assess safety and tolerability","timeFrame":"21 days after the first multiple dose"},{"measure":"Part A: To assess safety and tolerability","timeFrame":"Through the study completion, an average of around 1 year"},{"measure":"Part B: To assess anti-tumor activity","timeFrame":"Through the study completion, an average of around 1 year"}],"references":[],"start_date":{"date":"2025-05-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)","url":"https://clinicaltrials.gov/study/NCT06905197"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06905197"}